IBI363+IBI305

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

Conditions

EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

Trial Timeline

Aug 31, 2025 → Sep 30, 2028

NCT ID

NCT07124793

About IBI363+IBI305

IBI363+IBI305 is a phase 2 stage product being developed by Innovent Biologics for EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07124793. Target conditions include EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer.

What happened to similar drugs?

1 of 7 similar drugs in EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer were approved

Approved (1) Terminated (1) Active (5)

✅GefitinibAstraZenecaApproved

🔄AZD9291 + MEDI4736AstraZenecaPhase 3

🔄AZD9291 80mg oral each dayAstraZenecaPhase 3

🔄AZD9291 80 mg/40 mg + placebo + Placebo Erlotinib 150/100mg + Placebo Gefitinib 250 mg + Erlotinib 150/100 mg + Gefitinib 250 mg + Placebo AZD9291 80 mg/ 40 mgAstraZenecaPhase 3

🔄Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3

❌ERLOTINIB WITH CHEMOTHERAPY + CHEMOTHERAPY ONLYRochePhase 3

🔄Dacomitinib (PF-00299804) + GefitinibPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07124793	Phase 2	Recruiting	Aug 31, 2025	Sep 30, 2028	EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

Competing Products

20 competing products in EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

See all competitors

Product	Company	Stage	Hype Score
YH25448	Yuhan	Phase 1/2	32
YH32364	Yuhan	Phase 1/2	39
Datopotamab deruxtecan	Daiichi Sankyo	Pre-clinical	26
HER3-DXd	Daiichi Sankyo	Pre-clinical	26
ASP8273	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
erlotinib	Astellas Pharma	Phase 1	29
ASP8273 Capsules + ASP8273 Capsules A	Astellas Pharma	Phase 2	27
famitinib po + HS-10296 po	Jiangsu Hengrui Medicine	Phase 2	31
ABT-414	AbbVie	Pre-clinical	26
AZD9291 40 mg + AZD9291 80 mg	AstraZeneca	Phase 1	29
Osimertinib-based adaptive treatment + Osimertinib 80 MG	AstraZeneca	Phase 2	42
AZD9291 + MEDI4736	AstraZeneca	Phase 3	40
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)	AstraZeneca	Pre-clinical	22
AZD9291	AstraZeneca	Pre-clinical	26
Osimertinib	AstraZeneca	Phase 2	35
Dasatinib + Osimertinib	AstraZeneca	Phase 1/2	24
AZD9291 80mg oral each day	AstraZeneca	Phase 3	36
Tremelimumab + Durvalumab	AstraZeneca	Phase 2	31
Osimertinib	AstraZeneca	Phase 2	35